Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2)

Pharmaceutical Research

Volumn 24, Issue 4, 2007, Pages 811-815

  Uwai, Yuichi ^a   Ida, Hiroki ^a   Tsuji, Yoshie ^a   Katsura, Toshiya ^a   Inui, Ken Ichi ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Antivirals; Nephrotoxicity; Organic anion transporter; Renal transport

Indexed keywords

ADEFOVIR; ANTIVIRUS AGENT; CIDOFOVIR; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; PROBENECID; TENOFOVIR;

ARTICLE; CELL STRAIN HEK293; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG TRANSPORT; DRUG UPTAKE; EMBRYO; EMBRYO CELL; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CELL; KIDNEY TUBULE ABSORPTION; MONOLAYER CULTURE; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TRANSIENT EXPRESSION;

ADENINE; ANTIVIRAL AGENTS; CELL LINE; CYTOSINE; HUMANS; KIDNEY; KINETICS; ORGANIC ANION TRANSPORT PROTEIN 1; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT; ORGANIC CATION TRANSPORT PROTEINS; PHOSPHONIC ACIDS; PROBENECID; TRANSFECTION;

EID: 33947138325     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9196-x     Document Type: Article

References (18)

1. K. Inui, S. Masuda, and H. Saito. Cellular and molecular aspects of drug transport in the kidney. Kidney Int. 58:944-958 (2000).
2. H. Koepsell and H. Endou. The SLC22 drug transporter family. Pflugers Arch. 447:666-676 (2004).
3. J. W. Jonker and A. H. Schinkel. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J. Pharmacol. Exp. Ther. 308:2-9 (2004).
4. H. Miyazaki, T. Sekine, and H. Endou. The multispecific organic anion transporter family: properties and pharmacological significance. Trends Pharmacol. Sci. 25:654-662 (2004).
5. H. Motohashi, Y. Sakurai, H. Saito, S. Masuda, Y. Urakami, M. Goto, A. Fukatsu, O. Ogawa, and K. Inui. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol. 13:866-874 (2002).
6. D. H. Sweet. Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol. Appl. Pharmacol. 204:198-215 (2005).
7. A. Yonezawa, S. Masuda, K. Nishihara, I. Yano, T. Katsura, and K. Inui. Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem. Pharmacol. 70:1823-1831 (2005).
8. H. Izzedine, V. Launay-Vacher, and G. Deray. Antiviral drug-induced nephrotoxicity. Am. J. Kidney. Dis. 45:804-817 (2005).
9. T. Cihlar, E. S. Ho, D. C. Lin, and A. S. Mulato. Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids 20:641-648 (2001).
10. E. S. Ho, D. C. Lin, D. B. Mendel, and T. Cihlar. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. J. Am. Soc. Nephrol. 11:383-393 (2000).
11. Y. Sakurai, H. Motohashi, H. Ueo, S. Masuda, H. Saito, M. Okuda, N. Mori, M. Matsuura, T. Doi, A. Fukatsu, O. Ogawa, and K. Inui. Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm. Res. 21:61-67 (2004).
12. Y. Sakurai, H. Motohashi, K. Ogasawara, T. Terada, S. Masuda, T. Katsura, N. Mori, M. Matsuura, T. Doi, A. Fukatsu, and K. Inui. Pharmacokinetic significance of renal OAT3 (SLC22A8) for anionic drug elimination in patients with mesangial proliferative glomerulonephritis. Pharm. Res. 22:2016-2022 (2005).
13. H. Ueo, H. Motohashi, T. Katsura, and K. Inui. Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem. Pharmacol. 70:1104-1113 (2005).
14. Y. Urakami, M. Akazawa, H. Saito, M. Okuda, and K. Inui. cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J. Am. Soc. Nephrol. 13:1703-1710 (2002).
15. J. D. Schuetz, M. C. Connelly, D. Sun, S. G. Paibir, P. M. Flynn, R. V. Srinivas, A. Kumar, and A. Fridland. MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5:1048-1051 (1999).
16. S. Dallas, L. Schlichter, and R. Bendayan. Multidrug resistance protein (MRP) 4- and MRP 5-mediated efflux of 9-(2-phosphonylmethoxyethyl) adenine by microglia. J. Pharmacol. Exp. Ther. 309:1221-1229 (2004).
17. M. Leggas, M. Adachi, G. L. Scheffer, D. Sun, P. Wielinga, G. Du, K. E. Mercer, Y. Zhuang, J. C. Panetta, B. Johnston, R. J. Scheper, C. F. Stewart, and J. D. Schuetz. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol. Cell. Biol. 24:7612-7621 (2004).
18. H. Motohashi, Y. Uwai, K. Hiramoto, M. Okuda, and K. Inui. Different transport properties between famotidine and cimetidine by human renal organic ion transporters (SLC22A). Eur. J. Pharmacol. 503:25-30 (2004).